AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9101342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8300464 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 8300464 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 0
Study 3326410 — intervention group
Group type: COMPARATOR
Intervention: 40 mM acetate
Number of subjects: 12
Study 3326410 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mM DL‐lactate
Number of subjects: 12
Study 3326410 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mM each of acetate and DL‐lactate
Number of subjects: 12
Study 3326410 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate + lactate for a 3-week period
Number of subjects: 12
Study 31797492 — intervention group
Group type: EXPERIMENTAL
Intervention: BioVentrix Revivent TC System
Number of subjects: 89
Study 29367281 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of incarceration
Number of subjects: 3774
Study 27026388 — intervention group
Group type: EXPERIMENTAL
Intervention: CDE-delivered DSME/S with carbohydrate gram counting
Number of subjects: 150
Study 27026388 — intervention group
Group type: EXPERIMENTAL
Intervention: CDE-delivered DSME/S with modified plate method
Number of subjects: 150
Study 27026388 — intervention group
Group type: COMPARATOR
Intervention: General health education (control)
Number of subjects: 150
Study 27026388 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate counting (subgroup analysis)
Number of subjects: 150
Study 27026388 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified plate method (subgroup analysis)
Number of subjects: 150
Study 24970388 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol chocolate (HFC)
Number of subjects: 74
Study 24970388 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol chocolate (LFC)
Number of subjects: 74
Study 22182335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids (TIK) parenting program, six-session group program
Number of subjects: 128
Study 22182335 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 128
Study 20657533 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silver oxide ointment
Number of subjects: 148
Study 18981465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 500 mg
Number of subjects: 81
Study 18981465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg
Number of subjects: 81
Study 15467103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoseira canariensis supplementation (1200 mg/d)
Number of subjects: 22
Study 15467103 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (3 sets of 6 to 8 repetitions at 85% to 90% 1RM)
Number of subjects: 22
Study 15467103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 22
Study 11349938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 in low-fat milk (LFM)
Number of subjects: 52
Study 11349938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 in lactose-hydrolyzed low-fat milk (LFM-LH)
Number of subjects: 52
Study 11349938 — intervention group
Group type: COMPARATOR
Intervention: Run-in diet of LFM alone
Number of subjects: 52
Study 11349938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of HN001 consumption
Number of subjects: 52
Study 9716113 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 76
Study 9716113 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 76
Study 7987780 — intervention group
Group type: EXPERIMENTAL
Intervention: Group behavioral-cognitive therapy
Number of subjects: 24
Study 7987780 — intervention group
Group type: COMPARATOR
Intervention: Group behavioral-cognitive therapy with imipramine
Number of subjects: 24
Study 2602607 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil plus Isosorbide Dinitrate (120 mg verapamil + 20 mg isosorbide dinitrate)
Number of subjects: 12
Study 2602607 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg)
Number of subjects: 12
Study 2602607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 793956 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment with prednisone
Number of subjects: 2
Study 793956 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of prednisone
Number of subjects: 2
Study 31143396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel fortified with 0.5% chlorhexidine and 70% ethyl alcohol (in a volume ratio of 20:2:1)
Number of subjects: 20
Study 31143396 — intervention group
Group type: COMPARATOR
Intervention: Plain non-sterile gel
Number of subjects: 20
Study 28203021 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (ACB)
Number of subjects: 40
Study 28203021 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 40
Study 25017624 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducational intervention for 12 months
Number of subjects: 88
Study 25017624 — intervention group
Group type: COMPARATOR
Intervention: Normal standard treatment
Number of subjects: 88
Study 24640439 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive light-curing resin composite (Vertise Flow; Group 1)
Number of subjects: 75
Study 24640439 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Optibond All-in-One) combined with resin composite (Premise Flow; Group 2)
Number of subjects: 75
Study 24640439 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement (Ketac-Fil; Group 3)
Number of subjects: 75
Study 21241382 — intervention group
Group type: EXPERIMENTAL
Intervention: CIDR-EB (n = 17)
Number of subjects: 55
Study 21241382 — intervention group
Group type: EXPERIMENTAL
Intervention: CIDR-GnRH (n = 18)
Number of subjects: 55
Study 21241382 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 55
Study 18155704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone added to DMPA
Number of subjects: 0
Study 18155704 — intervention group
Group type: COMPARATOR
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 0
Study 16580907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg/d)
Number of subjects: 1
Study 16580907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide (150 mg/d)
Number of subjects: 1
Study 16580907 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of cetirizine and pilsicainide
Number of subjects: 1
Study 12742558 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol + 2 mg dienogest (30EE/DNG)
Number of subjects: 100
Study 12742558 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol + 2 mg dienogest (20EE/DNG)
Number of subjects: 100
Study 12742558 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg ethinylestradiol + 2 mg estradiol valerate + 2 mg dienogest (EE/EV/DNG)
Number of subjects: 100
Study 12742558 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol + 100 microg levonorgestrel (EE/LNG)
Number of subjects: 100
Study 12742558 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 100
Study 11759562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene (0.25 microgram/kg)
Number of subjects: 60
Study 11759562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11759562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 60
Study 9407174 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid detergent (pH 5.5)
Number of subjects: 40
Study 9407174 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact detergent (pH 5.5)
Number of subjects: 40
Study 9407174 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline soap (pH 9.5)
Number of subjects: 40
Study 9407174 — intervention group
Group type: COMPARATOR
Intervention: Tap water (control group)
Number of subjects: 40
Study 9407174 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 40
Study 9407174 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact detergent
Number of subjects: 40
Study 9407174 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid detergent
Number of subjects: 40
Study 8221821 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of extended-release isradipine for 30 days
Number of subjects: 16
Study 3767522 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP-antagonist, d(CH2)5Tyr(Me) AVP, 5 micrograms/kg i.v.
Number of subjects: 8
Study 3767522 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8
Study 29511007 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention (Sunface) delivered by medical students, implemented in classroom seminars lasting 45 minutes.
Number of subjects: 630
Study 28030547 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed educational toolkit
Number of subjects: 80
Study 28030547 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart audit and reflective feedback exercise
Number of subjects: 80
Study 28030547 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with family physicians
Number of subjects: 80
Study 24626140 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast training (CT) program (isometric + plyometric), no external loads, twice a week for 12 weeks
Number of subjects: 30
Study 24626140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 24626140 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 30
Study 24626140 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast training (CT) program
Number of subjects: 30
Study 23647956 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir monotherapy
Number of subjects: 49
Study 23647956 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir plus peginterferon alfa-2a and ribavirin (triple therapy)
Number of subjects: 49
Study 23647956 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus peginterferon alfa-2a and ribavirin (control)
Number of subjects: 49
Study 20133188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT‐I)
Number of subjects: 28
Study 20133188 — intervention group
Group type: COMPARATOR
Intervention: Contact control condition
Number of subjects: 28
Study 18937901 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier lifestyle intervention (increase in physical activity, reduction of body weight, regulation of calories and fat intake)
Number of subjects: 0
Study 18937901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle changes in patients with metabolic syndrome
Number of subjects: 0
Study 16698657 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT+ (hormone replacement therapy)
Number of subjects: 1458
Study 16698657 — intervention group
Group type: COMPARATOR
Intervention: HRT- (non-treated women)
Number of subjects: 1458
Study 12557135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose growth hormone (0.05 mg. kg(‐1). day(‐1))
Number of subjects: 12
Study 10376126 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg p.o. daily)
Number of subjects: 10
Study 10376126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8745894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5% w/w benzoyl peroxide and 3% w/w erythromycin
Number of subjects: 37
Study 8745894 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin alone
Number of subjects: 37
Study 8745894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of erythromycin and benzoyl peroxide
Number of subjects: 37
Study 1796233 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg daily x 3
Number of subjects: 92
Study 1796233 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg daily x 3
Number of subjects: 92
Study 1796233 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg daily x 7
Number of subjects: 92
Study 1796233 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (all groups)
Number of subjects: 92
Study 4073102 — intervention group
Group type: EXPERIMENTAL
Intervention: Timentin (ticarcillin plus clavulanic acid)
Number of subjects: 47
Study 4073102 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 47
Study 30114252 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance cues (e.g., photographs of watching eyes)
Number of subjects: 0
Study 30114252 — intervention group
Group type: COMPARATOR
Intervention: No surveillance cues (control group)
Number of subjects: 0
Study 27561827 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for 8 weeks (TG)
Number of subjects: 23
Study 27561827 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SG)
Number of subjects: 23
Study 27561827 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 23
Study 24853585 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinflammatory subphenotype (phenotype 2)
Number of subjects: 1022
Study 24853585 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP ventilation strategy
Number of subjects: 1022
Study 24853585 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP ventilation strategy
Number of subjects: 1022
Study 22840295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon visual educational instruction (group B)
Number of subjects: 0
Study 22840295 — intervention group
Group type: COMPARATOR
Intervention: Existing verbal and written instructions (group A)
Number of subjects: 0
Study 20826250 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker utilization at discharge
Number of subjects: 1971
Study 20826250 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker dosing categories at discharge
Number of subjects: 1971
Study 20826250 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker dose change between discharge and 3 weeks
Number of subjects: 1971
Study 20826250 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of very low beta-blocker doses
Number of subjects: 1971
Study 18456521 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid analgesics (NOAs), median intake of 1325 mg/week ibuprofen-equivalents (IE) for 46 subjects using NOAs
Number of subjects: 71
Study 18456521 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid analgesics (NOAs)
Number of subjects: 71
Study 17385969 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about upsetting experiences
Number of subjects: 0
Study 17385969 — intervention group
Group type: COMPARATOR
Intervention: Writing about trivial issues
Number of subjects: 0
Study 15584985 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose PLT transfusions (3 PLT units)
Number of subjects: 111
Study 15584985 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose PLT transfusions (5 PLT units)
Number of subjects: 111
Study 10859038 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin or low-molecular-weight heparin (LMWH)
Number of subjects: 17157
Study 10859038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 17157
Study 10859038 — intervention group
Group type: COMPARATOR
Intervention: Long-term low-molecular-weight heparin (LMWH)
Number of subjects: 17157
Study 9139212 — intervention group
Group type: COMPARATOR
Intervention: Individually dosed levothyroxine
Number of subjects: 78
Study 9139212 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms iodine
Number of subjects: 78
Study 9139212 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms levothyroxine combined with 100 micrograms iodine
Number of subjects: 78
Study 8363000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine (biochemical measure)
Number of subjects: 5887
Study 8363000 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide (biochemical measure)
Number of subjects: 5887
Study 8363000 — intervention group
Group type: COMPARATOR
Intervention: Self-report (compared with biochemical measures)
Number of subjects: 5887
Study 3707800 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 4.5, 8, 15, 25 or 50 mg/70 kg
Number of subjects: 40
Study 3707800 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 3, 5, 10 or 17.5 mg/70 kg
Number of subjects: 40
Study 3707800 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine (highest dose)
Number of subjects: 40
Study 31562889 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond™ Universal (SBU, 3 M) applied in self‐etch mode (SBU‐SE)
Number of subjects: 55
Study 31562889 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond™ Universal (SBU, 3 M) applied in selective‐enamel‐etch mode (SBU‐SEE)
Number of subjects: 55
Study 31562889 — intervention group
Group type: COMPARATOR
Intervention: OptiBond™ FL (OFL, Kerr)
Number of subjects: 55
Study 27753797 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP-T
Number of subjects: 550
Study 27753797 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV-HB//PRPT (control)
Number of subjects: 550
Study 27753797 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Number of subjects: 550
Study 26169094 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose esomeprazole (80 mg IV, then 8 mg/h continuous infusion for 3 days)
Number of subjects: 102
Study 26169094 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose esomeprazole (40 mg IV every 12 h for 72 h)
Number of subjects: 102
Study 22315471 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 123
Study 22315471 — intervention group
Group type: COMPARATOR
Intervention: High-definition white light endoscopy (HD-WLE)
Number of subjects: 123
Study 21890590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 30
Study 21890590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19383827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 18
Study 19383827 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 18
Study 17215611 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle enforcement program by biofeedback and electrical stimulation for 30 minutes per session, twice a week for 6 weeks, followed by self-exercise of pelvic floor muscle (50-60 repetitions per session, 3 times a day for 6 weeks)
Number of subjects: 49
Study 17215611 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 12780397 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation for severe non-proliferative retinopathy
Number of subjects: 344
Study 11002435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic pressure followed by general sustained stretching
Number of subjects: 40
Study 11002435 — intervention group
Group type: COMPARATOR
Intervention: Active range of motion (Control)
Number of subjects: 40
Study 9223884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine 0.1 mg (bolus injection)
Number of subjects: 120
Study 9223884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine 0.3 mg (continuous infusion)
Number of subjects: 120
Study 9223884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural droperidol 2.5 mg (bolus injection)
Number of subjects: 120
Study 9223884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural droperidol 5 mg (continuous infusion)
Number of subjects: 120
Study 8163613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (single injection at operative site during local anesthesia)
Number of subjects: 324
Study 8163613 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 324
Study 3019976 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (120 mg/m2 every 4 weeks)
Number of subjects: 45
Study 3019976 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cisplatin (80 mg/m2 every 3 weeks)
Number of subjects: 45
Study 30951160 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced EHR
Number of subjects: 38
Study 30951160 — intervention group
Group type: COMPARATOR
Intervention: Baseline EHR
Number of subjects: 38
Study 29087001 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (CMX)
Number of subjects: 187
Study 29087001 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 187
Study 26853206 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention delivered by MI-trained staff
Number of subjects: 164
Study 25226330 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted sled apparatus
Number of subjects: 10
Study 25226330 — intervention group
Group type: EXPERIMENTAL
Intervention: Back squat
Number of subjects: 10
Study 23071369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonuse of a bicycle helmet
Number of subjects: 129
Study 23071369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonuse of a bicycle helmet (excluding individuals younger than 18 years)
Number of subjects: 129
Study 23071369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonuse of a bicycle helmet (using a more stringent case definition)
Number of subjects: 129
Study 19844794 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 62568
Study 18030372 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable Spring Expander (RSE)
Number of subjects: 17
Study 18030372 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 17
Study 16102557 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestimate 180-250 microg/ethinyl estradiol 35 microg (NGM/EE)
Number of subjects: 27
Study 16102557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11182009 — intervention group
Group type: EXPERIMENTAL
Intervention: Data storage spirometer (Vitalograph)
Number of subjects: 90
Study 9734348 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal cord dysfunction (VCD) patients
Number of subjects: 0
Study 9734348 — intervention group
Group type: COMPARATOR
Intervention: Asthmatic controls
Number of subjects: 0